Keeping it real: implications of real-world treatment outcomes for first-line immunotherapy in metastatic non-small-cell lung cancer.

Hsu, Grace G; MacKay, Eric; Scheuer, Nicolas; Ramagopalan, Sreeram V

Hsu, Grace G; MacKay, Eric; Scheuer, Nicolas; Ramagopalan, Sreeram V.

Afiliação

Hsu GG; Cytel Inc, Toronto, ON, M5J 2P1, Canada.
MacKay E; Cytel Inc, Toronto, ON, M5J 2P1, Canada.
Scheuer N; Roche Products Ltd, Welwyn Garden City, AL7 1TW, UK.
Ramagopalan SV; Global Access, F Hoffmann-La Roche, Basel, 4070, Switzerland.

Immunotherapy ; 13(18): 1453-1456, 2021 12.

Article em En | MEDLINE | ID: mdl-34641707

ABSTRACT

ABSTRACT

Tweetable abstract Recent RWD studies suggest that the performance of immunotherapy in NSCLC is not as good as that seen in RCTs. However, analyses using RWD (and their interpretation) require careful appraisal and quantification of possible sources of bias.

Assuntos

Carcinoma Pulmonar de Células não Pequenas/mortalidade; Carcinoma Pulmonar de Células não Pequenas/terapia; Imunoterapia; Neoplasias Pulmonares/mortalidade; Neoplasias Pulmonares/terapia; Humanos; Intervalo Livre de Progressão; Taxa de Sobrevida

Palavras-chave

clinical trial; immunotherapy; non-small-cell lung cancer; quantitative bias assessment; real-world data; real-world evidence; synthetic control arms; target trial emulation

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Imunoterapia / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google